Recon: Pharma incensed by EU’s compulsory licensing proposal; FDA removes partial hold on Arcellx’s blood cancer drug

• DOJ blasts industry attempt to delay Medicare drug price negotiations (The Hill)
• 'Making it as simple as possible' Amazon Pharmacy offers insulin discounts amid price hikes (USA Today) (Reuters)
• As COVID-19 vaccine makers gear up to launch updated shots in the private market, can the new vaccines keep up with the virus? (Fierce Pharma)
• Persistence pays for Delcath as cancer treatment Hepzato Kit finally scores FDA nod (Fierce Pharma)
• FDA lifts partial hold on Arcellx’s Gilead-partnered blood cancer cell therapy as biotech aims for 2026 launch (Endpoints)
• Gilead ties up with Tentarix for cancer, inflammatory disease therapies (Reuters)
• Sandoz says its biosimilar matches Eylea in another threat to Regeneron's blockbuster (Fierce Pharma)
• Revance touts first therapeutic indication for Botox rival Daxxify in cervical dystonia (Endpoints)

• Pharma incensed by EU's compulsory licensing proposal (Pharmaphorum)
• Rule mandating doctors to prescribe generics may hit patient safety: IMA (Economic Times)
• UK's ITV invests in pain relief brand Flarin (Reuters)

• Catalent, facing pressure from Elliott, had other activists in stock (Reuters)
• Galecto scraps lung disease treatment after trial failure, shares tank (Reuters)
• How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B (Fierce Pharma)
• As former biotech leader Vivek Ramaswamy jumps in the presidential polls, what does he say for the life sciences brand? (Fierce Pharma)
• Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to front of pharma's growth pack in Q2 (Fierce Pharma)
• Exclusive: CSO George Yancopoulos talks Regeneron’s next chapter of genetics, weight loss drugs, and Alzheimer's (Endpoints)
• Following injection side effects, Design Therapeutics to reformulate Friedreich's ataxia drug, delay trial timeline (Endpoints)
• Takeda spinout HilleVax delays PhIIb norovirus topline data until mid-2024 over processing logistics (Endpoints)
• YouTube cracks down on misinformation on cancer treatment (STAT)
• From drug shortages to high prices, U.S. system’s shortcomings have deep roots (STAT)
• BMS, looking to build a market for a heart drug, turns to a Viz.ai algorithm to detect disease (STAT)
• Harmony Makes Rare Disease Play with Potential $200M Zynerba Buyout (BioSpace)

• Insulet claims EOFlow copied patch-pump design in patents (MedTech Dive)
• Medtronic’s bid to dismiss heart device kickback claims fails, clearing case to advance (MedTech Dive)
• Cue Health wins $28M BARDA contract to develop rapid respiratory infection test (MedTech Dive)

• Opioid Settlement Money Is Being Spent on Police Cars and Overtime (The New York Times)
• Enforcement Trends: CDER Presentation Confirms Fewer Warning Letters Are Issued by FDA for OAI Inspections (FDA Law Blog)
• SEC wants to know if key supplier of research monkeys bribed foreign officials (STAT)
• The best way for the NIH to reduce drug prices is to address drug spending (STAT)